XTX Topco Ltd Boosts Holdings in Danaher Co. (NYSE:DHR)

XTX Topco Ltd grew its position in Danaher Co. (NYSE:DHR) by 673.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,256 shares of the conglomerate’s stock after purchasing an additional 12,414 shares during the quarter. Danaher comprises approximately 0.3% of XTX Topco Ltd’s investment portfolio, making the stock its 29th biggest holding. XTX Topco Ltd’s holdings in Danaher were worth $3,562,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Tsfg LLC raised its position in shares of Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares during the last quarter. nVerses Capital LLC purchased a new position in shares of Danaher in the second quarter worth $25,000. CarsonAllaria Wealth Management Ltd. acquired a new stake in shares of Danaher during the second quarter worth $25,000. Cape Investment Advisory Inc. purchased a new stake in shares of Danaher during the fourth quarter valued at $25,000. Finally, Redmont Wealth Advisors LLC purchased a new position in Danaher in the 1st quarter worth $30,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Trading Down 0.2 %

Shares of DHR stock opened at $271.90 on Thursday. The stock has a market cap of $201.39 billion, a P/E ratio of 46.08, a P/E/G ratio of 4.48 and a beta of 0.83. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The business has a fifty day simple moving average of $266.50 and a 200-day simple moving average of $256.89.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the prior year, the company earned $2.05 EPS. Danaher’s revenue was down 2.9% on a year-over-year basis. On average, analysts forecast that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio is presently 18.31%.

Insider Transactions at Danaher

In related news, CFO Matthew Mcgrew sold 16,172 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the transaction, the chief financial officer now directly owns 29,407 shares in the company, valued at $8,229,254.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the transaction, the chief financial officer now owns 29,407 shares of the company’s stock, valued at $8,229,254.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The disclosure for this sale can be found here. Insiders have sold 39,659 shares of company stock worth $11,042,433 over the last quarter. 11.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

DHR has been the subject of several research analyst reports. Jefferies Financial Group started coverage on Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 price objective for the company. The Goldman Sachs Group upped their price objective on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Barclays raised their target price on shares of Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 24th. Stifel Nicolaus upped their price target on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Finally, TD Cowen lifted their price objective on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat, Danaher currently has an average rating of “Moderate Buy” and a consensus price target of $278.94.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.